Companies Merge to Form NeXstar

May 1, 1995

BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to form NeXstar Pharmaceuticals, Inc. One focus of the new company will be the liposomal delivery of oligonucleotides. The company's initial product, AmBisome, is a liposomal formulation of amphotericin B, which has been approved for marketing in 16 countries for the treatment of life-threatening systemic fungal infections that fail to respond to conventional amphotericin B therapy.

BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to formNeXstar Pharmaceuticals, Inc. One focus of the new company willbe the liposomal delivery of oligonucleotides. The company's initialproduct, AmBisome, is a liposomal formulation of amphotericinB, which has been approved for marketing in 16 countries for thetreatment of life-threatening systemic fungal infections thatfail to respond to conventional amphotericin B therapy.

A phase III trial of the product in conjunction with the NationalCancer Institute has recently been announced.